IGC Raises $3M Via Private Placement With Asset Management Firm Bradbury
Portfolio Pulse from Nabaparna Bhattacharya
IGC Pharma, Inc. has secured a $3 million investment from four funds managed by Bradbury Asset Management. The investment will be made through a private placement of ten million unregistered common shares at $0.30 each. The funds will be used to advance the company's Phase-2 clinical trial of IGC-AD1, a drug candidate for agitation in dementia caused by Alzheimer's disease.
July 06, 2023 | 2:27 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
IGC Pharma has raised $3 million through a private placement with Bradbury Asset Management. This will likely boost the company's ability to advance its Phase-2 clinical trial.
The $3 million investment will provide IGC with the necessary funds to advance its Phase-2 clinical trial of IGC-AD1. This could potentially lead to positive outcomes for the company, increasing investor confidence and potentially driving the stock price up.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100